Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis

Paschalis Vergidis, Mark S. Rouse, Gorane Euba, Melissa J. Karau, Suzannah M. Schmidt, Jayawant Mandrekar, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n = 16), linezolid plus rifampin (n = 14), or vancomycin plus rifampin (n = 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus- rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body.

Original languageEnglish (US)
Pages (from-to)1182-1186
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Linezolid
Osteomyelitis
Vancomycin
Rifampin
Methicillin-Resistant Staphylococcus aureus
Foreign Bodies
Animal Models

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. / Vergidis, Paschalis; Rouse, Mark S.; Euba, Gorane; Karau, Melissa J.; Schmidt, Suzannah M.; Mandrekar, Jayawant; Steckelberg, James M.; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 3, 03.2011, p. 1182-1186.

Research output: Contribution to journalArticle

Vergidis, Paschalis ; Rouse, Mark S. ; Euba, Gorane ; Karau, Melissa J. ; Schmidt, Suzannah M. ; Mandrekar, Jayawant ; Steckelberg, James M. ; Patel, Robin. / Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 3. pp. 1182-1186.
@article{2a43ab43a12d4b9f9f9cda9370e6948e,
title = "Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis",
abstract = "Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n = 16), linezolid plus rifampin (n = 14), or vancomycin plus rifampin (n = 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus- rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body.",
author = "Paschalis Vergidis and Rouse, {Mark S.} and Gorane Euba and Karau, {Melissa J.} and Schmidt, {Suzannah M.} and Jayawant Mandrekar and Steckelberg, {James M.} and Robin Patel",
year = "2011",
month = "3",
doi = "10.1128/AAC.00740-10",
language = "English (US)",
volume = "55",
pages = "1182--1186",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis

AU - Vergidis, Paschalis

AU - Rouse, Mark S.

AU - Euba, Gorane

AU - Karau, Melissa J.

AU - Schmidt, Suzannah M.

AU - Mandrekar, Jayawant

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2011/3

Y1 - 2011/3

N2 - Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n = 16), linezolid plus rifampin (n = 14), or vancomycin plus rifampin (n = 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus- rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body.

AB - Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n = 16), linezolid plus rifampin (n = 14), or vancomycin plus rifampin (n = 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus- rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body.

UR - http://www.scopus.com/inward/record.url?scp=79952339302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952339302&partnerID=8YFLogxK

U2 - 10.1128/AAC.00740-10

DO - 10.1128/AAC.00740-10

M3 - Article

C2 - 21189340

AN - SCOPUS:79952339302

VL - 55

SP - 1182

EP - 1186

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -